BRIEF published on 11/05/2025 at 13:51, 6 months 7 days ago Croissance continue pour Medincell et nouvelles perspectives avec l'Olanzapine LAI Schizophrénie Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 6 months 7 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
PRESS RELEASE published on 11/05/2025 at 13:46, 6 months 7 days ago Informations privilégiées / Autres communiqués Medincell annonce la poursuite de la croissance d'UZEDY® et la préparation du dépôt de l'Olanzapine LAI sur le marché américain par Teva Pharmaceuticals Croissance Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 10/10/2025 at 22:16, 7 months 1 day ago La FDA approuve UZEDY pour le traitement du trouble bipolaire de type I chez l'adulte Approbation De La FDA Traitement De Santé Mentale UZEDY Trouble Bipolaire I Risperidone
BRIEF published on 10/10/2025 at 22:16, 7 months 1 day ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 7 months 1 day ago Informations privilégiées / Autres communiqués La FDA approuve l’extension d’indication de UZEDY® pour le traitement de patients atteints de trouble bipolaire de type I par Teva Pharmaceuticals et Medincell FDA Medincell Teva Pharmaceuticals UZEDY Traitement Bipolaire
PRESS RELEASE published on 10/10/2025 at 22:11, 7 months 1 day ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 7 months 25 days ago Medincell et Teva présentent les données de phase 3 sur l'olanzapine LAI Essai De Phase 3 Traitement De La Schizophrénie Medincell Teva Olanzapine LAI
BRIEF published on 09/17/2025 at 14:05, 7 months 25 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 7 months 25 days ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
Published on 05/12/2026 at 21:42, 9 minutes ago Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026
Published on 05/12/2026 at 14:30, 7 hours 21 minutes ago Pathfinder Ventures Inc. Announces Conclusion of Financing and Intention to Launch New Private Placement
Published on 05/12/2026 at 14:30, 7 hours 21 minutes ago ACCESS Newswire Reports First Quarter 2026 Results
Published on 05/12/2026 at 13:50, 8 hours 1 minute ago Polaris Renewable Energy Announces Approval of SO1 Agreement by FOMB
Published on 05/12/2026 at 13:30, 8 hours 21 minutes ago Silver X Mining Begins Trading on OTCQX, Expanding Access to U.S. Investors
Published on 05/12/2026 at 20:21, 1 hour 29 minutes ago Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 2 hours 15 minutes ago AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 19:35, 2 hours 16 minutes ago 2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
Published on 05/12/2026 at 18:46, 3 hours 4 minutes ago LION E-Mobility Reports Q1 Results and Confirms Fiscal 2026 Outlook
Published on 05/12/2026 at 18:45, 3 hours 6 minutes ago Antitrust authority approval granted for the acquisition of a portfolio of rental units in Poland
Published on 05/12/2026 at 18:15, 3 hours 36 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 3 hours 36 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 3 hours 41 minutes ago imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 3 hours 41 minutes ago imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 4 hours 1 minute ago Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités
